Donaldson Company, Inc. reported its third quarter fiscal 2025 results on June 3, 2025, with net sales increasing 1.3% to $940.1 million compared to the prior year. The company achieved record adjusted earnings per share (EPS) of $0.99, a 7.6% increase, and raised its full-year adjusted EPS guidance to between $3.64 and $3.70.
However, GAAP net earnings significantly decreased to $57.8 million, or $0.48 per share, from $113.5 million in the prior year. This decline was primarily due to $65.8 million in pre-tax, non-recurring net charges, including a $62.0 million impairment charge related to certain intangible assets for two upstream bioprocessing businesses, Univercells Technologies and Solaris.
The impairment reflects weak capital spending in bioprocessing and longer-than-anticipated drug development timelines. Despite these challenges, Mobile Solutions aftermarket sales rose 3.3%, Industrial Solutions sales increased 5.3%, and Life Sciences sales grew 0.7%. The company also accelerated share repurchases, buying back 3.3% of outstanding shares year-to-date, and announced an 11.1% increase to its quarterly dividend.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.